Drug Approval | May 05, 2026
Lupin receives USFDA approval for generic Ravicti oral liquid
Approval expands Lupin’s specialty portfolio in the US market for treatment of urea cycle disorders
Approval expands Lupin’s specialty portfolio in the US market for treatment of urea cycle disorders
The company says the product will now be distributed exclusively through Anovo Specialty Pharmacy
Approval marks the second generic semaglutide clearance in Canada and strengthens OneSource’s position in complex injectable CDMO programs
Pharma and healthcare stocks stay in focus as investors track earnings, USFDA approvals, hospital growth, and global market pressures
The company’s Growth Portfolio delivered $6.2 billion in revenue
The microbiology unit generated $645 million in revenue in 2025 and sits within Thermo Fisher’s Specialty Diagnostics segment
The company posted revenue of €1,267 million, up 6% on a constant currency basis
Reshaped by COVID-19, rising test demand, and a shift toward decentralized diagnostics, qPCR has evolved from niche academic use to a core clinical engine
Market authorization for generic GLP-1 therapy strengthens company’s diabetes portfolio in Canada
Subscribe To Our Newsletter & Stay Updated
